SCHEMBL3117372

SCHEMBL3117372

CCNC(=O)c1ccc(-n2nnc(C(=O)O)c2CCCOCc2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 1/20 0.42
BRD4 O60885 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
POLB P06746 2/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
OPRM1 P35372 3/20 0.38
OPRD1 P41143 3/20 0.38
PPARG P37231 2/20 0.38
TP53 P04637 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3108747 0.95 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3112021 0.89 GLS (0.40) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3107172 0.89 RAB9A (0.40) ALDH1A1SMN1; SMN2POLBRAB9ANPC1
SCHEMBL3112223 0.89 PPARG (0.40) ALDH1A1CYP1A2HPGDSMN1; SMN2POLB
SCHEMBL3100909 0.88 ALDH1A1 (0.47) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3117389 0.88 MLYCD (0.38) ALDH1A1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL3107237 0.87 ALDH1A1 (0.46) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3109619 0.86 HPGD (0.48) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3115010 0.86 MAPK11 (0.41) CYP1A2CYP2C9CYP2C19BRD4SMN1; SMN2
SCHEMBL3099846 0.85 GLS (0.41) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 ALDH1A1 3580/4885CYP1A2 418/4885CYP2C9 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.